Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 369,057 |
|
|||||
| News | - | ||||||
| Day High | 1.38 | Low High |
|||||
| Day Low | 1.30 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Ikena Oncology Inc | IKNA | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.01 | -0.76% | 1.31 | 23:00:10 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.35 | 1.30 | 1.38 | 1.31 | 1.32 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,108 | 369,057 | US$ 1.32 | US$ 487,910 | - | 1.02 - 7.64 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 16:29:18 | 2 | US$ 1.32 | USD |
Ikena Oncology Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 63.22M | 48.26M | - | 9.16M | -68.17M | -1.41 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Ikena Oncology News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IKNA Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.30 | 1.38 | 1.28 | 1.32 | 159,401 | 0.01 | 0.77% |
| 1 Month | 1.37 | 1.44 | 1.22 | 1.31 | 211,111 | -0.06 | -4.38% |
| 3 Months | 1.40 | 1.65 | 1.22 | 1.43 | 403,181 | -0.09 | -6.43% |
| 6 Months | 4.11 | 4.625 | 1.02 | 1.49 | 330,128 | -2.80 | -68.13% |
| 1 Year | 5.76 | 7.64 | 1.02 | 2.46 | 215,500 | -4.45 | -77.26% |
| 3 Years | 24.90 | 26.4899 | 1.02 | 5.66 | 160,430 | -23.59 | -94.74% |
| 5 Years | 22.40 | 37.61 | 1.02 | 6.72 | 166,126 | -21.09 | -94.15% |
Ikena Oncology Description
| Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. |
